Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.45 USD | -2.10% |
|
-0.14% | -10.14% |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
06-11 | Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.14% | 2.39B | |
+27.04% | 52.73B | |
+37.49% | 39B | |
-9.36% | 38.52B | |
+28.58% | 30.38B | |
-12.26% | 26.39B | |
+11.76% | 26.08B | |
+45.18% | 14.15B | |
+32.85% | 12.6B | |
-5.46% | 11.51B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Insider Sell: Celldex Therapeutics